ArticleBMC nephrology2026
Renal potassium wasting from hydroxychloroquine at therapeutic doses: a case report.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydroxychloroquine is a common disease-modifying treatment for systemic autoimmune disease and is usually well-tolerated. In acute hydroxychloroquine or chloroquine toxicity, hypokalemia typically reflects a transient intracellular potassium shift rather than true renal potassium losses. Persistent hypokalemia due to renal potassium wasting during therapeutic hydroxychloroquine use has not been well described. CASE PRESENTATION: A 38-year-old woman with undifferentiated connective tissue disease developed recurrent symptomatic hypokalemia while receiving therapeutic hydroxychloroquine. She had normal renal function and blood pressure, and was not using diuretics or laxatives. Urine studies demonstrated inappropriate renal potassium loss during hypokalemia. Holding hydroxychloroquine for two weeks resulted in normalization of serum potassium levels, accompanied by symptom resolution. Rechallenge at a dose of 300 mg daily reproduced hypokalemia, which again resolved after drug discontinuation. DISCUSSION/
conclusionThe temporal relationship, objective urine indices, normalization after withdrawal, and recurrence with rechallenge suggest hydroxychloroquine-associated renal potassium wasting. The underlying mechanism remains uncertain and is hypothesized to involve tubular effects during chronic exposure. Clinicians should confirm the mechanism with urine studies when hypokalemia persists on hydroxychloroquine, consider a supervised medication hold when feasible, and pair potassium repletion with a potassium-sparing agent if the drug must continue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.